Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) is projected to post its quarterly earnings results before the market opens on Monday, March 3rd. Analysts expect Nektar Therapeutics to post earnings of ($0.18) per share and revenue of $36.65 million for the quarter.
Nektar Therapeutics Price Performance
NKTR traded up $0.02 during trading on Thursday, reaching $0.80. 1,307,413 shares of the company's stock were exchanged, compared to its average volume of 2,405,204. Nektar Therapeutics has a 1 year low of $0.65 and a 1 year high of $1.93. The company's fifty day simple moving average is $0.91 and its 200-day simple moving average is $1.11. The stock has a market capitalization of $146.87 million, a P/E ratio of -0.95 and a beta of 0.58.
Insider Activity
In related news, insider Jonathan Zalevsky sold 51,115 shares of the business's stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the sale, the insider now directly owns 326,904 shares in the company, valued at approximately $307,289.76. The trade was a 13.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Andrew Wilson sold 33,402 shares of the firm's stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total value of $30,061.80. Following the completion of the transaction, the insider now owns 351,892 shares in the company, valued at $316,702.80. The trade was a 8.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 165,586 shares of company stock worth $159,990 in the last quarter. Corporate insiders own 3.71% of the company's stock.
Wall Street Analysts Forecast Growth
NKTR has been the subject of a number of research reports. HC Wainwright restated a "buy" rating and set a $6.50 target price on shares of Nektar Therapeutics in a research report on Tuesday. William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Tuesday. Piper Sandler initiated coverage on Nektar Therapeutics in a research report on Monday, November 4th. They issued an "overweight" rating and a $7.00 price objective on the stock. Finally, B. Riley started coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $4.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.08.
Get Our Latest Research Report on NKTR
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Featured Articles
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
